Investigational drug · Phase 3
zelicapavir
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for RSV, RSV Infection, Respiratory Syncytial Virus (RSV).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "zelicapavir"
First trial start
2026
Jul 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zelicapavir", any sponsor or status.
Conditions studied
As listed on its trial records.
- RSV
- RSV Infection
- Respiratory Syncytial Virus (RSV)
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "zelicapavir" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07908381 · 860 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 2029
Drug: zelicapavir; Placebo · For: RSV
Sites: Cape Coral, Florida; Miami, Florida; Bluffton, South Carolina · 4 sites in all
- A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusPivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07482657 · 150 participants (planned) · Start Jul 9, 2026 · Primary completion Dec 2026
Drug: zelicapavir; Placebo · For: RSV Infection; RSV; Respiratory Syncytial Virus (RSV)
Sites: Bangkok, Thailand; Chiang Mai, Thailand; Chiang Rai, Thailand · 8 sites in all
- A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsCompleted
Enanta Pharmaceuticals, IncIndustry
NCT06601192 · 72 participants · Start Jul 15, 2024 · Primary completion Feb 2, 2025
Drug: zelicapavir (therapeutic dose); zelicapavir (supratherapeutic dose) and 2 more · For: RSV Infection; QTc Interval
Sites: Lenexa, Kansas; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy.
Herron JC, Link KG, Meacham N, et al. · CPT Pharmacometrics Syst Pharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.